Low rate of cmv end-organ disease in hiv-infected patients despite low cd4+ cell counts and cmv viremia: Results of ACTG protocol a5030

HIV Clinical Trials

Volumn 10, Issue 3, 2009, Pages 143-152

  Wohl, D A ^a   Kendall, M A ^b   Andersen, J ^b   Crumpacker, C ^c   Spector, S A ^d   Feinberg, J ^e   Alston Smith, B ^f   Owens, S ^g   Chafey, S ^h   Marco, M ⁱ   Maxwell, S ^j   Lurain, N ^k   Jabs, D ^l   Benson, C ^d   Keiser, P ^m   Jacobson, M A ⁿ  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CINCINNATI   (United States)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

^g FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ Och Spine at New York Presbyterian Hospitals   (United States)

^j UNIVERSITY OF WASHINGTON   (United States)

^k RUSH UNIVERSITY MEDICAL CENTER   (United States)

^l MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^m UNIVERSITY OF TEXAS AT DALLAS   (United States)

ⁿ UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

AIDS; CMV; Opportunistic disease prevention; Valganciclovir

Indexed keywords

GANCICLOVIR; PLACEBO; VALGANCICLOVIR; VIRUS RNA;

ADULT; AIDS PATIENT; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS; DNA DETERMINATION; DRUG DOSE INCREASE; DRUG WITHDRAWAL; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TERMINAL DISEASE; VIREMIA;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DOUBLE-BLIND METHOD; GANCICLOVIR; HIV INFECTIONS; HUMANS; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROPORTIONAL HAZARDS MODELS; VIREMIA;

EID: 69249145207     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct1003-143     Document Type: Article

References (14)

1. Drew WL. Cytomegalovirus infection in patients with AIDS. Clin Infect Dis. 1992;14:608-615.
2. Jackson JB, Erice A, Englund JA, Edson JR, Balfour HH. Prevalence of cytomegalovirus antibody in hemophiliacs and homosexuals infected with human immunodeficiency virus type 1. Transfusion. 1988;28:187-189.
3. Lang DJ, Kovacs AA, Zaia JA, et al. Seroepidemiologic studies of cytomegalovirus and Epstein-Barr virus infections in relation to human immunodefi ciency virus type 1 infection in selected recipient populations. J Acquir Immune Defi c Syndr. 1989;2:540-549.
4. Clarke LM, Duerr A, Feldman J, et al. Factors associated with cytomegalovirus infection among human immunodefi ciency virus type 1-seronegative and seropositive women from an urban minority community. J Infect Dis. 1996;173(1):77-82.
5. Spector SA, Wong R, Hsia K, et al. Plasma cytomegalovirus (CMV) DNA load predicts CMV disease and survival in AIDS patients. J Clin Invest. 1998;101:497-502.
6. Spector SA, Hsia K, Crager M, et al. Cytomegalovirus (CMV) DNA load is an independent predictor of CMV disease and survival in advanced AIDS. J Virol. 1999;73:7027-7030.
7. Casado JL, Arrizabalaga J, Montes M, et al. Incidence and risk factors for developing cytomegalovirus retinitis in HIV-infected patients receiving protease inhibitor therapy. AIDS. 1999;13:1497-1502.
8. Salmon-Ceron D, Mazeron MC, Chaput S, et al. Plasma cytomegalovirus DNA, pp65 antigenaemia and a low CD4 cell count remain risk factors for cytomegalovirus disease in patients receiving highly active antiretroviral therapy. AIDS. 2000;14(8):1041-1049.
9. Erice A, Tierney C, Hirsch M, et al. Cytomegalovirus (CMV) and human immunodeficiency virus (HIV) burden, CMV end-organ disease, and survival in subjects with advanced HIV infection (AIDS Clinical Trials Group Protocol 360). Clin Infect Dis. 2003;37:567-578.
10. Deayton JR, Sabin CA, Johnson MA, et al. Importance of cytomegalovirus viremia in risk of disease progression and death in HIV-infected patients receiving highly active antiretroviral therapy. Lancet. 2004;363:2116-2121.
11. Wohl DA, Zeng D, Stewart P, et al. Cytomegalovirus viremia, mortality, and end-organ disease among patients with AIDS receiving potent antiretroviral therapies. J Acquir Immune Defic Syndr. 2005;38(5):538-544.
12. Regulatory Compliance Center, Division of AIDS. Table for grading the severity of adult and pediatric adverse events. Available at: http://rcc.tech-res.com/tox-tables. html. Accessed February 8, 2009
13. Fundus Photography Reading Center, University of Wisconsin. Nine Standard Field Protocol for Fundus Photography. Available at: http://eyephoto.ophth. wisc.edu/ Photography/Protocols/AIDS/AIDSPhotoProtocol.html. Accessed February 8, 2009
14. Gray RJ. A class of k-sample test for comparing the cumulative incidence of a competing risk. Ann Statistics. 1988;16:1141-1154.